A STABILIZED HIRUDIN SOLID PREMIX IN THE TRANSLATIONAL CONTEXT OF CORONARY THROMBOSIS AND ACUTE CORONARY ISCHEMIA

Anas Ziraoui; Aditya Prakoso; Misaki Kimura

doi:10.61796/jhsm.v1i4.39

Authors

Anas Ziraoui National Standards Laboratory SA, Switzerland
Aditya Prakoso National Standards Laboratory SA, Switzerland
Misaki Kimura National Standards Laboratory SA, Switzerland

DOI:

https://doi.org/10.61796/jhsm.v1i4.39

Keywords:

Hirudin, acute coronary syndrome, coronary thrombosis, direct thrombin inhibition, water activity, peptide stabilization, antithrombotic therapy

Abstract

Objective: Persistent thrombin activity contributes to coronary thrombosis and recurrent ischemia in acute coronary syndromes. We measured hirudin activity in a low-water-activity premix and reviewed randomized evidence from unstable angina and non-ST-elevation acute coronary syndromes. Method: Optimized BCLC® formulations retained 90.6-92.1% antithrombin activity at water activity values of 0.26-0.34. High-humidity processing produced the highest water activity (0.49) and lowest retention (72.9%); without citrate buffer, retention was 80.1%. An angiographic unstable-angina trial reported dose-related antithrombotic effects of recombinant hirudin. In GUSTO-IIb, 12,142 patients were randomized, and death or myocardial infarction at 24 h occurred in 1.3% with hirudin and 2.1% with heparin. OASIS-2 enrolled 10,141 patients with non-ST-elevation acute myocardial ischemia. Results: At 7 days, cardiovascular death or new myocardial infarction occurred in 3.6% with hirudin and 4.2% with heparin; treatment-period analyses favored hirudin, but major bleeding requiring transfusion was higher. These trials establish both pharmacodynamic activity and a dose-safety context. Novelty: The premix data permit oral exposure and coagulation biomarkers to be examined from a defined activity level.

References

[1] E. J. Topol et al., “Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial,” Circulation, vol. 89, no. 4, pp. 1557–1566, 1994, doi: 10.1161/01.CIR.89.4.1557.

[2] The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators, “A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes,” N. Engl. J. Med., vol. 335, no. 11, pp. 775–782, 1996, doi: 10.1056/NEJM199609123351103.

[3] Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators, “Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study,” Circulation, vol. 96, no. 3, pp. 769–777, 1997, doi: 10.1161/01.CIR.96.3.769.

[4] Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators, “Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial,” Lancet, vol. 353, no. 9151, pp. 429–438, 1999, doi: 10.1016/S0140-6736(98)07332-2.

[5] K. Kottke-Marchant et al., “Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy,” Eur. Heart J., vol. 23, no. 15, pp. 1202–1212, 2002, doi: 10.1053/euhj.2001.3074.

[6] K. L. Kaplan and C. W. Francis, “Direct thrombin inhibitors,” Semin. Hematol., vol. 39, no. 3, pp. 187–196, 2002, doi: 10.1053/shem.2002.34092.

[7] A. Greinacher and T. E. Warkentin, “The direct thrombin inhibitor hirudin,” Thromb. Haemost., vol. 99, no. 5, pp. 819–829, 2008, doi: 10.1160/TH07-11-0693.

[8] Direct Thrombin Inhibitor Trialists’ Collaborative Group, “Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients’ data,” Lancet, vol. 359, no. 9303, pp. 294–302, 2002, doi: 10.1016/S0140-6736(02)07495-0.

[9] P. H. Johnson, “Hirudin: Clinical potential of a thrombin inhibitor,” Annu. Rev. Med., vol. 45, pp. 165–177, 1994, doi: 10.1146/annurev.med.45.1.165.

[10] P. Eichler, H. J. Friesen, N. Lubenow, B. Jaeger, and A. Greinacher, “Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance,” Blood, vol. 96, no. 7, pp. 2373–2378, 2000, doi: 10.1182/blood.V96.7.2373.

[11] A. Greinacher, N. Lubenow, and P. Eichler, “Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia,” Circulation, vol. 108, no. 17, pp. 2062–2065, 2003, doi: 10.1161/01.CIR.0000096056.37269.14.

[12] X. Xu et al., “Self-regulated hirudin delivery for anticoagulant therapy,” Sci. Adv., vol. 6, no. 41, Art. no. eabc0382, 2020, doi: 10.1126/sciadv.abc0382.

[13] F. Schiele et al., “Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomized trial,” Thromb. Haemost., vol. 77, no. 5, pp. 834–838, 1997, PMID: 9184388.

[14] B. I. Eriksson et al., “A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement,” N. Engl. J. Med., vol. 337, no. 19, pp. 1329–1335, 1997, doi: 10.1056/NEJM199711063371901.

[15] M. Verstraete et al., “Biologic effects of recombinant hirudin (CGP 39393) in human volunteers,” J. Am. Coll. Cardiol., vol. 22, no. 4, pp. 1080–1088, 1993, doi: 10.1016/0735-1097(93)90419-2.